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ABSTRACT
Objectives: To determine: (1) the pharmacokinetics and safety of an investigational
aminoquinoline active against multidrug–resistant malaria parasites (AQ-13), including its
effects on the QT interval, and (2) whether it has pharmacokinetic and safety profiles similar to
chloroquine (CQ) in humans.
Design: Phase I double-blind, randomized controlled trials to compare AQ-13 and CQ in
healthy volunteers. Randomizations were performed at each step after completion of the
previous dose.
Setting: Tulane–Louisiana State University–Charity Hospital General Clinical Research Center
in New Orleans.
Participants: 126 healthy adults 21–45 years of age.
Interventions: 10, 100, 300, 600, and 1,500 mg oral doses of CQ base in comparison with
equivalent doses of AQ-13.
Outcome Measures: Clinical and laboratory adverse events (AEs), pharmacokinetic
parameters, and QT prolongation.
Results: No hematologic, hepatic, renal, or other organ toxicity was observed with AQ-13 or
CQ at any dose tested. Headache, lightheadedness/dizziness, and gastrointestinal (GI) tract–
related symptoms were the most common AEs. Although symptoms were more frequent with
AQ-13, the numbers of volunteers who experienced symptoms with AQ-13 and CQ were similar
(for AQ-13 and CQ, respectively: headache, 17/63 and 10/63, p¼0.2; lightheadedness/dizziness,
11/63 and 8/63, p¼0.6; GI symptoms, 14/63 and 13/63; p¼0.9). Both AQ-13 and CQ exhibited
linear pharmacokinetics. However, AQ-13 was cleared more rapidly than CQ (respectively,
median oral clearance 14.0–14.7 l/h versus 9.5–11.3 l/h; p   0.03). QTc prolongation was
greater with CQ than AQ-13 (CQ: mean increase of 28 ms; 95% confidence interval [CI], 18 to 38
ms, versus AQ-13: mean increase of 10 ms; 95% CI, 2 to 17 ms; p ¼ 0.01). There were no
arrhythmias or other cardiac AEs with either AQ-13 or CQ.
Conclusions: These studies revealed minimal differences in toxicity between AQ-13 and CQ,
and similar linear pharmacokinetics.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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PLoS CLINICAL TRIALSINTRODUCTION
Malariaisanoverwhelminglyimportantpublichealthproblem
withupto3–4billioncasesand3milliondeathseachyear[1,2].
In terms of malaria control and human health, chloroquine
(CQ) was the most important antimalarial for more than 40
years because of its efﬁcacy, safety, and affordability [3–5].
However, since the ﬁrst reports of CQ-resistant Plasmodium
falciparum in the 1960s [6,7] and the subsequent spread of CQ
resistance across Southeast Asia, South America and sub-
Saharan Africa [8], the single most important factor in the
worldwide morbidity and mortality of malaria has been the
increasing prevalence of CQ resistance in P. falciparum [9,10].
Recent studies by ourselves and others have shown that
aminoquinolines (AQs) with modiﬁed side chains are active
against CQ-resistant P. falciparum in vitro [11–13]. Subse-
quently, we have shown that these AQs are as safe as CQ in
mice and monkeys (Cogswell, et al., unpublished data), and
are active in two monkey models of human malaria (P.
cynomolgi in rhesus monkeys [14], which is a model of P. vivax
infection in humans, and CQ-resistant P. falciparum in squirrel
monkeys [15], which is a model of human CQ-resistant P.
falciparum infection). The next step was to conduct a Phase I
randomized clinical trial (RCT) to determine the safety and
the pharmacokinetic behavior of the lead compound, AQ-13,
in healthy volunteers (Figure 1).
Selection of AQ-13 as the Lead Compound
Criteria for the selection of AQ-13 as the lead compound
were: (1) in vitro activity against CQ-susceptible and –
resistant P. falciparum, (2) activity in monkey models of human
P. vivax and CQ-resistant P. falciparum infection, (3) safety, and
(4) affordability. Based on these criteria, three AQs (AQ-13,
AQ-21, and AQ-34) each could have been the initial lead
compound. However, AQ-34, which has an isopropyl side
chain, was dropped from consideration because the chiral
center on its side chain resulted in two enantiomers. Because
an additional (optical) puriﬁcation would have been required
to separate those enantiomers, the cost of pure AQ-34 would
have been greater than that of AQ-13 or AQ-21. In addition,
further studies would have been required to compare the
activities and toxicities of the two enantiomers. Between AQ-
13 and AQ-21 (which have linear propyl and ethyl side
chains), AQ-13 (Figure 2) was chosen as the lead compound
because it was more active in monkey models of human
malaria (Cogswell, et al., unpublished data).
Preclinical Studies of AQ-13 in Comparison with CQ
After AQ-13 had been selected as the initial lead compound,
preclinical studies were performed to examine its toxicology
and pharmacokinetics in animals in comparison with CQ
[16,17].Becausethosestudiesrevealednodifferencesintoxicity
between AQ-13 and CQ and similar pharmacokinetics, an
Investigational New Drug Application was ﬁled with the US
Food and Drug Administration (IND 55,670) [18]. The rationale
of that application was that an AQ active against CQ-resistant
P. falciparum that was as safe and economical as CQ would be a
major advance: because the few drugs effective against CQ-
resistant P. falciparum are too expensive for use by the
impoverished residents of malaria-endemic countries [19–21],
because malaria parasites are already developing resistance to
theexpensiveantimalarialsnowinuse[22,23],andbecausethere
are unresolved concerns about the safety of the antimalarials
now used to treat CQ-resistant P. falciparum [24,25].
Based on this information, the Phase I clinical trial
reported here was performed as a series of RCTs to
determine whether there were signiﬁcant differences in
toxicity (safety) or pharmacokinetics between AQ-13 and
CQ in human volunteers.
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Editorial Commentary
Background: Chloroquine (CQ) is a drug that has been widely used for
over 40 years for the treatment and prevention of malaria. It is cheap,
safe, and, except in areas where resistant malaria parasites exist,
effective. However, the spread of resistant malaria parasites in most
malarial regions of the world has meant that this drug, and many others,
can no longer be relied upon to control disease. New drug candidates
are therefore needed, and ideally should be cheap to produce as well as
safe and effective. Some research groups are working on potential drug
candidates from the aminoquinoline family of compounds, which
includes chloroquine. One candidate, AQ-13 (aminoquinoline-13) has
already been studied in animal and in vitro experiments, and seemed to
be a good candidate for further testing in humans. Therefore, as the first
stage in evaluating AQ-13 further, this group of researchers carried out a
Phase I trial in healthy humans. The researchers specifically wanted to
compare how often people given AQ-13, as compared to those given
CQ, had side effects, and to find out how AQ-13 is handled in the body
(i.e., how quickly the compound is taken into the bloodstream, gets
broken down, and how it affects normal body functions). These sorts of
studies do not tell researchers anything about the efficacy of the drug in
treating malaria, but the results are absolutely essential before trials can
be done that do test efficacy in people with malaria. 126 healthy
volunteers were recruited into the study, and each received capsules
containing a different dosage of either AQ-13 or CQ. Side effects data
were collected for four weeks after the drugs were given.
What this trial shows: The most common side effects experienced by
volunteers in the trial were headache, light-headedness, dizziness, and
gastrointestinal symptoms such as nausea, vomiting, and diarrhea.
Overall, the frequencies of such events were roughly similar among
people receiving AQ-13 and those receiving CQ, but due to the small
numbers of participants in the trial, it is not possible to say whether any
observed differences in frequency of side effects between the two
groups are meaningful or not. The data collected in this trial also showed
that both AQ-13 and CQ were absorbed into the bloodstream in a similar
way, but AQ-13 was absorbed more slowly than CQ. On ECG testing,
both compounds increased the QT interval (part of the heart’s electrical
cycle, and used as a measure of heart function), particularly at high
dosage levels, and volunteers given CQ experienced a greater increase in
QT interval than those receiving AQ-13. No volunteers experienced any
symptoms related to heart function. The researchers concluded that on
the basis of these data, AQ-13 could proceed to further trials to evaluate
the drug’s efficacy in treating clinical malaria.
Strengths and limitations: The trial was appropriately designed as a
randomized controlled Phase I study, allowing the researchers to assess
safety and physiological outcomes after giving AQ-13 as compared to an
existing and widely used drug, CQ. A key limitation inherent to such
studies is the small number of participants studied. This means that the
study cannot prove that AQ-13 is safe, or even as safe as CQ, but rather
simply that the findings do not raise immediate safety concerns.
Contribution to the evidence: Data from animal experiments suggest
that AQ-13 could potentially be a safe and effective antimalarial
compound. The results reported here provide crucial safety data from
the first study known to this research group that evaluates the effects of
AQ-13 in humans.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.METHODS
Participants
Healthy volunteers from 21 to 45 years of age were invited to
participate in these studies. Exclusion criteria included
pregnancy, breast-feeding, abnormal liver or kidney function
tests, anemia (hemoglobin , 12 g/dl), chronic medications
other than birth control pills, and an abnormal electro-
cardiogram (ECG) or Holter recording. Inpatient and out-
patient studies were performed at the Tulane–Louisiana State
University (LSU)–Charity Hospital General Clinical Research
Center (GCRC) in New Orleans, Louisiana, United States.
There were two rationales for performing the Phase I
studies of AQ-13 in the United States rather than in a malaria-
endemic area: (1) ethical concerns of developing country
colleagues and potential participants about drugs developed
in the US are resolved most effectively by data indicating that
the agent to be studied has been tested and shown to be safe
in American volunteers, and (2) FDA regulatory staff required
safety data from the US before considering studies of an
investigational antimalarial in sub-Saharan Africa.
Informed consent was obtained from each volunteer before
screening, based on a consent form approved by the Tulane
Institutional Review Board. In addition, an independent Data
Safety and Monitoring Board approved by National Institutes
of Health, FDA, and the US Centers for Disease Control and
Prevention reviewed the results for each dose with the
principal investigator (DJK) and his colleagues before
providing their permission to proceed to the next dose.
The members of the Data Safety and Monitoring Board and
their afﬁliations are listed below in the Acknowledgments
section. Enrolment of volunteers began in August 1999 and
follow-ups were completed in August 2005. Data entry was
concluded in September 2005.
Interventions
Participants were allocated randomly to receive the new
candidate drug, AQ-13, or CQ. Sixteen volunteers were
Figure 1. Phase 1 Randomized Clinical Trial of AQ-13 in Comparison with CQ
Designed as a series of double-blind RCTs at incremental oral doses of 10, 100, 300, 600, and 1,500 mg, with a 700 mg adjustment dose after 600 mg to ensure
similar bioavailability for AQ-13 and CQ at the 1,500/1,750 mg dose (based on the area under the curve, AUCs,i nh3lM, as in Figure 3). *AQ-13 dosages: 700þ
700 þ 350 mg on days 1, 2, and 3, respectively; CQ dosages: 600 þ 600 þ 300 mg on days 1, 2, and 3, respectively.
doi:10.1371/journal.pctr.0020006.g001
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Randomized Controlled Trial of AQ-13randomized to receive AQ-13 or CQ (eight each) at doses of
10, 100, or 300 mg base. At the 600 mg dose, 36 volunteers
were randomized (12 each) to AQ-13 capsules, CQ capsules,
or Sanoﬁ-Winthrop CQ tablets (Aralen). AQ-13 was produced
as the dihydrochloride, trihydrate salt under Good Manufac-
turing Practice (GMP) conditions by Starks Associates
(Buffalo, New York, United States) and CQ as the phosphate
salt by Sanoﬁ-Winthrop (New York, New York, United States).
Using this GMP material, University Pharmaceuticals (Balti-
more, Maryland, United States) and SRI International (Menlo
Park, California, United States) produced color-coded cap-
sules containing equal molar doses of AQ-13 and CQ. Quality
assurance and dissolution tests were performed by University
Pharmaceuticals, SRI International and RTI (Research Tri-
angle, North Carolina, United States) [18]. The third arm
(commercially available CQ tablets) was included at the
request of the FDA to determine whether there were
differences between the CQ capsules prepared from GMP
CQ phosphate (Sanoﬁ-Winthrop) and commercially available
CQ phosphate tablets (Aralen). Before the 1,500 mg ther-
apeutic dose, 13 volunteers received a 700 mg adjustment
dose of AQ-13 to compensate for the more rapid clearance of
AQ-13. At the next stage of the Phase I study, 29 volunteers
were randomized to receive either the standard therapeutic
dose of 1,500 mg CQ base over 3 d or an equivalent 1,750 mg
dose of AQ-13 (based on the adjustment dose).
Outpatient screening and inpatient admission. To deter-
mine their eligibility, all volunteers had a complete physical
exam, including an eye examination (visual acuity, visual
ﬁelds, indirect ophthalmoscopy), were screened for hemato-
logic and chemical abnormalities (complete blood count,
chemistry panel including aspartate aminotransferase [AST],
alanine aminotransferase [ALT], alkaline phosphatase, gam-
ma-glutamyl transpeptidase [Gamma-GT], lactate dehydro-
genase [LDH], bilirubin, creatinine, blood urea nitrogen
[BUN], and fasting glucose), and for arrhythmias and other
evidence of cardiac disease (physical exam, ECG, 24-hour
Holter recording). Weight was measured by an electronic
scale and height with a wall-mounted meter stick (Seca 216
Stadiometer, HealthCheck Systems, Brooklyn, New York,
United States). Body mass index (BMI) was calculated using
the formula: BMI ¼ weight (kg)/height
2 (m
2).
Eligible volunteers were admitted as inpatients to the
GCRC. Urine pregnancy testing was performed at the time
of screening and again the evening before drug administra-
tion. Creatine kinase testing was also performed twice: at the
time of screening and again on the evening of admission.
Volunteers remained in the GCRC for 2.5–3.5 d depending on
the AQ dose: 2.5 d for the 10, 100, 300, 600 mg and adjustment
doses; 3.5 d for the 1,500/1,750 mg therapeutic dose.
AQ administration, and blood and urine samples for drug
and metabolite levels. Study drugs were administered in the
GCRC on an empty stomach between 8 and 9 AM the
morning after admission (after fasting for   10 h). For the
ﬁrst three doses, volunteers received single capsules contain-
ing 10, 100, or 300 mg CQ base or an equivalent molar
amount of AQ-13 (9.1, 91.3, or 273.8 mg AQ-13 base, Figure
1). For the 600 mg dose and the 700 mg adjustment dose,
volunteers received two 300 or 350 mg AQ-13 capsules (547.5
or 638.8 mg AQ-13 base) or two 300 mg CQ capsules, as a
single morning dose. For the 1,500/1,750 mg therapeutic dose,
volunteers received two 350 mg AQ-13 capsules or two 300
mg CQ capsules on days 1 and 2, and a single 350 mg AQ-13
or 300 mg CQ capsule on day 3 for doses of 1,750 mg AQ-13
(1,596.9 mg AQ-13 base) or 1,500 mg CQ.
Blood samples for drug and metabolite levels were obtained
after the 600 mg dose, the 700 mg adjustment dose, and the
1,500/1,750 mg therapeutic dose, but not after the 10, 100, or
300 mg doses. Blood samples (5 ml) were drawn 0, 1, 2, 4, 6, 12,
18, 24, 48, 72, 96, and 120 hours after beginning AQ-13 or CQ
administration, and twice weekly thereafter, up to 4 weeks.
Follow-up urine and blood samples. In addition to the
blood samples, twenty-four hour urine collections were
obtained for 3 d after the 1,500/1,750 mg therapeutic dose
to evaluate the urinary excretion of AQ-13, CQ, and their
metabolites. Concentrations of AQ-13, CQ, and their metab-
olites were measured in whole blood and 24-hour urines with
a ﬂuorescence high-performance liquid chromatography
(HPLC) assay using an Xterra RP18 analytical column with
an elution buffer containing 60% borate (20 mM, pH 9.0) and
40% acetonitrile. Quantitation was based on the peak:area
ratios for AQ-13, CQ, and their metabolites in relation to the
internal standard [26].
Measurement of effects of AQ-13 and CQ on the QT
interval. Afterthe600mgAQ-13andCQdosesandthe700mg
(adjustment) AQ-13 dose, the QT interval was measured
electronically from ECG recordings. The effects of the study
drugs on the QT interval were assessed by comparing QT
Figure 2. Structures of AQ-13, CQ, and Their Metabolites
Two-dimensional structures are presented. Note that the AQ rings of AQ-13
and CQ are identical; the structural differences between AQ-13 and CQ are in
their side chains: linear propyl side chain for AQ-13, branched isopentyl side
chain for CQ. Therefore, the molecular weight (MW) of AQ-13 (292 Da) is 28
Da less than CQ (320 Da). Metabolism by N-dealkylation converts an ethyl
group to a hydrogen (proton) at each step, resulting in stepwise MW
differences of 28 Da.
doi:10.1371/journal.pctr.0020006.g002
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Randomized Controlled Trial of AQ-13intervals before dosing with QT intervals 4 h after dosing, and
atthe2wkfollow-up.Afterthe1,750and1,500mgdosesofAQ-
13 and CQ, continuous 5 d Holter recordings were used to
compare the effects of AQ-13 and CQ on the QT interval
adjusted for a heart rate different from 60 beats per minute
(QTc). Three 1-min recordings were examined from before
dosing(baseline),from4and5haftereachdose,andfrom24h
after the last dose. QT intervals were measured manually and
electronically(RozinnElectronics,Glendale,NewYork,United
States).Recordingsobtained48hafterthelastdose,ontheﬁfth
day of Holter monitoring, were not used for analysis because
they were of poor quality. Correction of the QT interval for
heartrate(i.e.,QTc)wasperformedusingBazett’sformula[27].
Recording and reporting of adverse events. Adverse events
(AEs) were recorded in weekly diaries provided to each
volunteer. The relatedness of these AEs to the study drugs was
assessed by two physicians (FM, CH) based on temporal
association and biological plausibility using ﬁve categories:
deﬁnitely not, unlikely, possibly, probably, and deﬁnitely
related. The AEs reported in this manuscript include all AEs
assessed as possibly, probably, or deﬁnitely related. The one
disagreement between these physicians was resolved by the
principal investigator (DJK).
Objectives
The basic and preclinical studies of AQ-13 and CQ [11–13,16–
18] generated two hypotheses for the Phase I human studies:
AQs structurally similar to CQ were likely to: (1) be safe in
human volunteers, and (2) have side effects (AEs) and
pharmacokinetics (blood levels and bioavailability) similar
to those of CQ. Because AQ-13 was cleared more rapidly than
CQ in the preclinical studies [17,18], the protocol for the
Phase I human studies included a dose adjustment step after
the 600 mg dose (Figure 1). Because the information available
about the effects of CQ on the QT interval was limited
[28,29], these studies used Holter recordings to compare the
effects of CQ and AQ-13 on the QT interval.
Thus, the objectives of this Phase I trial were to determine:
(1) the pharmacokinetics and safety of an investigational AQ
active against resistant malaria parasites (AQ-13) [11–13],
including its effects on the QTc interval, and (2) whether AQ-
13 is likely to have pharmacokinetic and safety proﬁles
similar to chloroquine (CQ) in humans. To address these
questions, we performed a series of double-blind RCTs with
incremental oral doses of AQ-13 and CQ equivalent to 10,
100, 300, 600, and 1,500 mg CQ base.
Outcomes
Primary outcomes (endpoints) for the RCTs comparing
incremental oral doses of AQ-13 and CQ included their
pharmacokinetics, clinical and laboratory adverse events
(AEs), and their effects on the QT interval. Pharmacokinetic
parameters were calculated using the WinNonlin software
(Pharsight, Mountain View, California, United States); they
included: maximal drug concentration in the blood (Cmax),
time from oral administration to Cmax (Tmax), total area
under the curve (AUCs), terminal elimination half-life (t1/2),
mean residence time (MRT), apparent oral clearance (Cl/F)
and apparent volume of distribution (Vd/F). Clinical AEs were
symptoms assessed as possibly, probably or deﬁnitely drug-
related by the blinded physician reviewers that occurred
within four weeks of drug administration. Laboratory AEs
were abnormal hematologic or chemical test results identiﬁed
within 4 d of drug administration or at the 2 or 4 wk follow-
up. The effects of AQ-13 and CQ on the QT interval were
deﬁned in relation to the baseline QT interval, before AQ-13
or CQ administration.
Secondary outcomes (endpoints) evaluated were the
pharmacokinetics of AQ-13 and CQ metabolites, pruritus
after receiving AQ-13 or CQ, and ocular AEs [3,4,30–34].
Sample Sizes
Sample sizes chosen for the lower doses (10, 100, and 300 mg)
were eight in each group (AQ-13 and CQ) in order to detect
one or more severe AEs in each dose–drug group with
probabilities of 94% and 83%, assuming AE rates of 30% and
20%, respectively. Sample sizes chosen for the higher doses
(600, 700, 1,500, and 1,750 mg) were 12 or 13 in each group in
order to obtain a minimum of ten evaluable participants for
pharmacokinetic studies within each dose–drug group and
thus to detect one or more severe AEs in each dose–drug
group with probabilities of 99%, 93%, and 72% based on AE
rates of 30%, 20%, and 10%.
Randomization
Volunteers who agreed to participate in the study, satisﬁed the
inclusion and exclusion criteria, and completed their baseline
studies were randomized to one of two or three treatments.
Assignments of individuals to two treatments, A and B, were
prepared by the study statistician by permuting blocks of four
(A,A,B,B) and six (A,A,A,B,B,B) with a random number
generator in a stepwise fashion—envelopes were prepared
for each dose after the previous dose had been completed. The
blocks of four and six were randomized so that block size was
unknown to the investigators. For the comparison of three
treatments, a similar procedure was performed for blocks of
six (A,A,B,B,C,C) and nine (A,A,A,B,B,B,C,C,C). There was no
stratiﬁcation in this study. Assignments were then hand-
delivered to the study pharmacist in opaque, sealed, num-
bered envelopes. On the morning(s) of drug administration,
the study pharmacist opened those envelopes and dispensed
the indicated drug (AQ-13 or CQ).
Blinding
Neither the volunteers, the clinical or laboratory staff, nor
the investigators knew which drugs the participants had
received. Allocation codes and study drugs were controlled by
the study pharmacist in the hospital pharmacy, which was
outside the GCRC. Study drugs were dispensed the morning
after admission after a phone call from the charge nurse
indicating that a new volunteer had been admitted and was
ready for drug administration. Interim data were reported to
the Data Safety and Monitoring Board without breaking the
code. Results and comparisons were reported for volunteers
in two groups at the 10, 100, 300, and 1,500/1,750 mg doses
(groups 1 and 2), and in three groups at the 600 mg dose
(groups 1, 2, and 3). The staff, nurses, and investigators caring
for volunteers in the GCRC and evaluating the relatedness of
AEs to the study drugs were blinded; i.e., they did not know
which drugs the participants had received.
Statistical Methods
Drug concentration data for each participant were ﬁtted to a
noncompartmental pharmacokinetic (PK) model in order to
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Randomized Controlled Trial of AQ-13estimate PK parameters using the WinNonlin 4.1 software
(Pharsight). A noncompartmental model with extravascular
input was chosen because it required fewer assumptions and
because it better described the blood-concentration data [35].
Partial areas under the curve (partial AUCs) were calculated
using the linear trapezoidal method up to the last blood
concentration; total AUCs were then estimated by adding the
extrapolated AUC from the last measurement to inﬁnity [35].
Because the near-horizontal terminal slopes of the concen-
tration–time data made the estimates of the extrapolated part
of the area under the curve less reliable, oral clearance (Cl/F)
was calculated from the formula (Cl/F ¼ dose/AUCobs), where
AUCobs is the partial AUC based on the empirically observed
data (for 4 wk). The multiple-dose model for the 1,500/1,750
mg therapeutic doses was derived using the nonparametric
superposition method [35]. MRT was estimated using the
statistical moments approach: (MRT ¼ AUMC/AUC), where
AUMC is the area under the ﬁrst-moment concentration-
time curve. Renal clearance (Clr) was estimated from the
means of the renal clearances for the three 24-h urine
samples collected on days 1–3 after dosing, using the formula
(Clr ¼ X/pAUC) where X is the amount of the compound
excreted in the urine, and pAUC is the partial blood AUC for
the day of the urine sample. Because the terminal portions of
the concentration–time curves for the metabolites were
virtually ﬂat in some cases, data for curves in which the
extrapolated AUC exceeded 65% of the total AUC were not
included in the analysis.
Quantitative data are presented as the mean 6 standard
deviation or as median and range, as appropriate. Fisher
exact test or Pearson chi-square was used to compare the
frequencies of the AEs reported for AQ-13 and CQ at each
dose, and between African Americans and persons of Euro-
pean descent. Due to a lack of normality, the nonparametric
Mann-Whitney U test was used to compare independent
samples; the Wilcoxon or Friedman test (whichever was
appropriate) was used to compare repeated measures of the
QTc interval. All statistical tests were two-sided with an a
(signiﬁcance level) of 0.05. Analyses were performed using the
SPSS 11.0 statistical software (SPSS, Chicago, Illinois, United
States). All analyses were based on allocation by intent-to-
treat. The small differences in the number of participants (n)
across the tables in ‘‘Results’’ are due to the different
numbers of missing data points for different outcomes.
This study had 70% power to detect a 50% difference in the
frequency of AEs, assuming a 40% frequency of AEs in the
control group (CQ). This power is based on combined dose
groups,excludingthe10mgdose.Atthe600/700mgdoselevel,
this study had 80% power to detect a difference of 12 ms or
greater in the mean change of the QTc interval from baseline.
At the 1,750/1,500 mg doses, this study had 80% power to
detect a difference of 15 ms or greater in the mean change of
the QTc interval from baseline. All power calculations were
performed using variances estimated from the study data.
RESULTS
Recruitment of Volunteers and Participant Flow
A total of 215 volunteers were screened to obtain 175 eligible
participants (Figure 1). The remaining 40 volunteers were
ineligible because they had abnormal chemistry or hematol-
ogy lab results, abnormal ECGs or Holter recordings, or other
health problems. Of the 175 eligible volunteers, 49 decided
not to enroll or were lost because of scheduling conﬂicts or
delays between screening and enrollment. Three volunteers
withdrew after enrolment at the 1,500/1,750 mg dose; the
participation of one volunteer was terminated by the super-
vising physician because of otitis media, and two volunteers
dropped out for reasons unrelated to AEs after two doses
(Figure 1). Of the 123 volunteers who received the planned
doses of AQ-13 or CQ, 26 missed one or more of the eight
follow-up visits, and 97 completed each of the follow-up visits.
Available AE and Holter data for the three participants who
withdrew were included in the analyses.
Baseline Data and the Results of Randomization
Based on age, sex, race, weight, BMI, and the baseline QTc
interval, there were no signiﬁcant differences between
volunteers randomized to AQ-13 versus CQ (Table 1). When
baseline characteristics were compared at the different dose
levels, there was a signiﬁcant difference between the AQ-13
and CQ groups in mean weight (but not BMI) only at the 100
mg dose (unpublished data).
Numbers Analyzed
All the 63 participants who received AQ-13 and the 63 who
received CQ were analyzed for AEs, including those who
withdrew before completing the intended dose. Holter data
were available on 14 out of the 15 participants who received
1,500 mg CQ, and on 13 out of 14 participants who received
1,750 mg AQ-13, and were all included in the analysis.
Outcomes and Estimation
Frequency of AEs. The AEs reported most frequently were
headache and lightheadedness/dizziness, which were distrib-
uted similarly among volunteers randomized to AQ-13 and
CQ (Table 2). Headache was reported by 31 of 126 volunteers;
27 of those 31 reports were assessed as drug-related by the
blinded physician reviewers. Of the 27 drug-related reports of
headache, 17/63 (27%) were in volunteers who received AQ-
13 and 10/63 (16%) were in volunteers who received CQ (p ¼
0.2). Lightheadedness/dizziness ﬁrst appeared at the 300 mg
dose level and was reported by 24/126 volunteers. Nineteen of
those 24 reports were assessed as drug-related (11/63 and 8/63
for AQ-13 and CQ, respectively; p¼0.6). Gastrointestinal (GI)
.......................................................................................
Table 1. Randomization of Volunteers to AQ-13 and CQ:
Baseline Characteristics
Characteristic AQ-13 (n ¼ 50)
a CQ (n ¼ 63) p-Value
Age (years) 29.2 6 6.4 28.7 6 5.3 0.92
b
Gender 21 (M), 29 (F) 29 (M), 34 (F) 0.71
c
Ethnicity 28 (W), 18 (AA), 4 (O) 38 (W), 24 (AA) 0.16
c
Weight (kg) 74.4 6 19.4 75.8 6 18.6 0.68
b
BMI (kg/m
2) 25.5 6 6.0 26.1 6 6.9 0.84
b
QTc interval (ms) 400 6 19 402 6 20 0.70
b
aExcluding 13 volunteers who received the 700 mg adjusted dose of AQ-13 without
randomization.
bFisher exact test.
cMann-Whitney test.
AA, African American; F, female; M, male; O, other; W, of European descent.
doi:10.1371/journal.pctr.0020006.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Randomized Controlled Trial of AQ-13tract symptoms were the next most common AEs (nausea,
diarrhea, vomiting, abdominal pain, loss of appetite), and ﬁrst
appeared at the 600 mg dose. The numbers of volunteers
reporting one or more GI symptoms were similar in the two
groups (AQ-13, 14/63; CQ, 13/63; p ¼ 0.9). However, drug-
related GI symptoms were reported more frequently by
volunteers who received AQ-13 (28 reports) than volunteers
who received CQ (20 reports), because GI symptoms were
more clustered in volunteers treated with AQ-13. Other
symptoms, such as mild, transient eye (blurred vision,
difﬁculty focusing, ﬂoating objects) or ear symptoms (changes
in hearing, ringing in the ears), mild skin rash (one volunteer
had a sparse maculopapular erythematous eruption on the
lower torso), and fatigue were infrequent and occurred at
similar frequencies in both groups. CQ pruritus was not
reported by any of the volunteers. Because of the small
numbers of volunteers studied at each dose, no signiﬁcant
conclusions can be drawn from comparisons of AEs between
drugs at the individual dose levels. There were no differences
in the incidence of AEs between African American volunteers
and those of European descent (p ¼ 0.63).
Post-dose clinical and laboratory follow-up. There was no
clinical evidence for end-organ toxicity after either AQ-13 or
CQ during the daily inpatient examinations, or at the 2 or 4
wk outpatient follow-up. Speciﬁcally, there was no evidence
for cardiac, dermatologic, hepatic, hematologic, ocular, or
other organ toxicity.
Repeat laboratory testing 4 d after drug administration
revealed no hematologic or chemical toxicities with either
AQ-13 or CQ. At the 2 wk follow-up, two volunteers who
received AQ-13 and two who received CQ had mildly
abnormal liver function tests (AQ-13: one participant with a
bilirubin of 1.5 mg/dl, another participant with an AST of 135
U/l, an ALT of 149, and an alkaline phosphatase of 146; CQ:
one participant with a bilirubin of 1.7 and another with an
ALT of 50). The two volunteers who received AQ-13 had
received the 100 and 300 mg doses; the two volunteers who
received CQ had both received the 1,500 mg dose. Follow-up
test results were normal for all participants at the times of the
3 and 4 wk outpatient visits.
Pharmacokinetics of AQ-13 and CQ. The 600 mg doses of
AQ-13 and CQ were absorbed rapidly after oral adminis-
tration (Figure 3). Blood levels of AQ-13 and CQ peaked at
similar times (Tmax 4.0 h [1.0–8.0 h] and 3.0 h [1.0–8.0 h] for
AQ-13 and CQ), but had different maximal concentrations
(Cmax 1.4 lM [0.9–2.4 lM] and 1.8 lM [1.3–5.2 lM] for AQ-13
and CQ; p , 0.01), and the absorption of CQ was slightly
more rapid than AQ-13 (Table 3). One hour after dosing, the
CQ blood level was 72% of the CQ Cmax versus 52% for AQ-
13. AQ-13 had a shorter terminal elimination t1/2 than CQ
(14.3 [6.2–39.3 d] versus 23.3 d [10.2–54.6 d]; p , 0.01), a
shorter MRT (10.5 d [6.0–37.4 d] versus 24.7 d [12.4–49.8 d]; p
, 0.01), a smaller AUCs (140.8 h 3 lM [63.4–351.9] versus
241.2 h 3 lM [179.8–432.4]; p , 0.01), and was cleared more
rapidly (Cl/F¼14.7 l/h [7.0–31.1 l/h] versus 11.3 l/h [5.7–20.3 l/
h]; p ¼ 0.01) (Table 3). However, no PK differences were
observed between the results obtained with the GMP CQ
capsules and the standard CQ tablets available commercially
(Aralen, p   0.15 for all PK parameters).
With the 700 mg adjustment dose of AQ-13, the lower Cmax
and the smaller AUCs of AQ-13 at the 600 mg dose (Figure
3A; Table 3) indicate that AQ-13 is less bioavailable than CQ,
cleared more rapidly than CQ, or both. To compensate for
the apparent lower bioavailability of AQ-13 and achieve
similar systemic exposure (based on the AUC)—in order to
compare the safety of AQ-13 and CQ—the AQ-13 dose was
increased (adjusted) to 700 mg and compared with the 600 mg
dose of CQ (Figure 3B and 3C). Because the major metabolite
of AQ-13 (mono-N-dealkylated AQ-13) is not active against
CQ-resistant parasites, this adjustment was based on the
AUCs for the parent compound (AQ-13), and did not
consider either of its metabolites. The 700 mg dose of AQ-
13 was administered to 13 healthy volunteers using the same
protocol. The 700 mg dose of AQ-13 produced a larger AUCs
than 600 mg CQ, but a similar ﬁrst-week partial AUC
(AUCw1), and a similar mean Cmax (Table 3). Based on these
results, the 1,500 therapeutic dose of CQ was compared with
1,750 mg of AQ-13 in the last part of the study.
In the comparison of the 1,500 mg therapeutic dose of CQ
with 1,750 mg AQ-13, the 1,750 mg AQ-13 dose produced a
smaller AUCs than 1,500 mg CQ, although this difference was
of borderline signiﬁcance (p ¼ 0.09; Table 4). The more
clinically relevant AUCw1 and mean Cmax tended to be lower
in volunteers who received AQ-13 than in volunteers who
received CQ, although these differences were not signiﬁcant
(p ¼ 0.3). These results are consistent with the 600/700 mg
dose because AQ-13 was cleared more rapidly than CQ (Cl/F¼
14.0 l/h [6.8–20.3 l/h] and 9.5 l/h [5.4–20.6 l/h]; p ¼ 0.03).
However, the terminal elimination t½ and MRT were similar
.......................................................................................
Table 2. FrequencyofRelatedAdverseEventsbyDrugandDose
Dose (mg) Adverse Event AQ-13 CQ
10 — n ¼ 8 n ¼ 8
None 0 0
100, 300 — n ¼ 16 n ¼ 16
Headache 2 (12%) 1 (6%)
Lightheadedness/Dizziness 0 1 (6%)
Nausea 1 (6%) 0
600/700
a — n ¼ 25 n ¼ 24
Headache 10 (40%) 5 (21%)
Lightheadedness/Dizziness 4 (16%) 3 (13%)
Loss of appetite 3 (12%) 3 (13%)
Nausea 2 (8%) 1 (4%)
Diarrhea 2 (8%) 2 (8%)
Vomiting 2 (8%) 0
Abdominal pain 2 (8%) 0
Ear symptoms 0 2 (8%)
1,500/1,750
b — n ¼ 14 n ¼ 15
Headache 5 (36%) 4 (27%)
Lightheadedness/dizziness 7 (50%) 4 (27%)
Loss of appetite 4 (28%) 2 (13%)
Nausea 5 (36%) 5 (33%)
Diarrhea 4 (29%) 4 (27%)
Vomiting 2 (14%) 2 (13%)
Abdominal pain 1 (7%) 0
Weakness/fatigue 2 (14%) 0
Blurred vision 2 (14%) 2 (13%)
Difficulty focusing/visual floating objects 2 (14%) 3 (20%)
a24 volunteers received 600 mg CQ tablets or CQ capsules; 12 received an AQ-13 dose
equivalent to 600 mg of CQ (547.5 mg AQ-13 base); and 13 received an AQ-13 dose
equivalent to 700 mg of CQ (638.8 mg of AQ-13).
bCQ: 600, 600 and 300 mg on days 1, 2, and 3; AQ-13: 700, 700 and 350 mg on days 1,
2, and 3.
doi:10.1371/journal.pctr.0020006.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Randomized Controlled Trial of AQ-13Figure 3. Pharmacokinetics of AQ-13 and CQ at Doses Equivalent to 600 and 700 mg CQ Base
Charts of blood concentration data for individual volunteers during the first week (168 h) after: 600 mg dose of AQ-13 (A), 700 mg dose of AQ-13 (B), or 600m g
dose of CQ (C). Individual volunteers received single oral doses of 600 mg AQ-13 or CQ, or 700 mg AQ-13. Blood samples of 5 ml were then obtained at multiple
points in time after drug administration (see Methods) and examined using a fluorescence HPLC assay for AQ-13, CQ, and their N-dealkylated metabolites [34].
Modeling was performed using the WinNonlin software (Pharsight).
doi:10.1371/journal.pctr.0020006.g003
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Randomized Controlled Trial of AQ-13with AQ-13 and CQ (p ¼ 0.87, p ¼ 0.89; Table 4). With both
AQ-13 and CQ, peak blood concentrations were achieved 3–4
h after the second dose (27–28 h after the ﬁrst dose).
Pharmacokinetics of AQ-13 and CQ metabolites. Mono-N-
dealkylated AQ-13 and CQ (AQ-72 and MDCQ) are the major
metabolites of AQ-13 and CQ [33]. Both AQ-72 and MDCQ
appeared in the blood within 1 h after the oral administration
of 600 or700 mg of AQ-13 or600 mg of CQ (Table 5), and were
identiﬁed in all but two of 60 participants (one each with AQ-
13 and CQ). Although the di-dealkylated metabolites of AQ-13
and CQ (AQ-73, BDCQ) were not detected in the blood, they
were identiﬁed in urine collections from days 1–3 after dosing.
The pharmacokinetics of AQ-72, the initial metabolite of
AQ-13 (600 mg AQ-13), were similar to those of the parent
drug (median MRT of 16.6 d [10.5–51.8 d] for AQ-72 versus
10.5 d [6.0–37.4 d] for AQ-13; p ¼ 0.16; median terminal
elimination t1/2 of 11.1 d [6.8–37.0 d] for AQ-72 versus 14.3 d
[6.2–39.3 d] for AQ-13; p ¼ 0.67). The median Cmax of AQ-72
was 0.59 lM (0.25–0.76 lM) with a median Tmax of 15 h (8.0–
48.0 h). At the Cmax of AQ-13, the AQ-72/AQ-13 ratio varied
widely with a mean of 0.37, which increased rapidly thereafter
and reached 1.0 3–6 d after drug administration.
In contrast, the pharmacokinetics of MDCQ, the initial
metabolite of CQ (600 mg CQ), were different from those of
CQ; MDCQ had a longer MRT and terminal t1/2 than CQ
(median MRT of 44.8 d [20.8–71.0 d] versus 24.7 d [12.4–49.8
d]; p , 0.01; median terminal t1/2 of 31.2 d [13.1–59.5 d] for
MDCQ versus 23.3 d [10.2–54.6 d] for CQ; p¼0.01). At the CQ
Cmax, the MDCQ/CQ ratio was 0.26; it then increased slowly
until it reached 1.0 2–3 wk after dosing. Despite the lower Cmax
of MDCQ, the AUCs values for MDCQ and CQ were similar
(MDCQ 204.8 [122.6–419.9]; CQ 241.2 [179.8–432.4]; p ¼ 0.32)
because of the longer terminal elimination t1/2 with MDCQ.
In a comparison of AQ-72 and MDCQ (600 mg AQ-13/CQ),
estimates of Cmax were similar for AQ-72 and MDCQ (0.59 lM
[0.25–0.76 lM] versus 0.54 lM [0.32–0.89 lM]; p ¼ 0.26).
However, MDCQ had a longer median MRT than AQ-72 (44.8
d [20.8–71.0 d] versus 16.6 d [10.5–51.8 d]; p , 0.01), and a
longer terminal elimination t1/2 (31.2 d [13.1–59.5 d] versus
11.1 d [6.8–37.0 d]; p , 0.01). Similar results for both AQ-72
and MDCQ were obtained at the 1,750/1,500 mg doses, except
MRT was shorter with MDCQ at the 1,500 mg dose than at the
600 mg dose (Table 5).
The amounts of unchanged drug recovered from 24 hour
urine collections on days 1–3 were 8.4% and 18.0% of the
totaloral doses of AQ-13 and CQ, respectively (443 lmol [304–
645 lmol] and 829 lmol [530–1,202 lmol]). Although the AQ-
72/AQ-13 and MDCQ/CQ ratios in urine were similar (23.6%
and 22.7%), when comparing the ratios of the second
metabolite to the parent drugs, the AQ-73/AQ-13 ratio was
twiceaslargeastheBDCQ/CQratio(5.2%and2.6%forAQ-73
and BDCQ), consistent with more effective conversion of AQ-
13 to its mono- and di-dealkylated metabolites, more rapid Clr
of AQ-73 than BDCQ, or both. The Clr of AQ-13 was less than
that of CQ (p¼0.01; Table 4). Similarly, the renal clearance of
AQ-72 was less than that of MDCQ (p , 0.01; Table 5).
Effects of AQ-13 and CQ on the QT Interval
Baseline QTc intervals. Mean 6 standard deviation (range)
baseline QTc intervals were similar in the AQ-13 and CQ
groups (Table 6). At the 600/700 mg dose level, QTc interval
duration was 403 6 17 ms (376–445 ms), and 406 6 19 ms
(369–448 ms) for AQ-13 and CQ (p¼0.65), while at the 1,500/
1,750 mg dose level QTc was 397 6 16 ms (373–421 ms) and
396 6 21 ms (362–430 ms) for AQ-13 and CQ (p ¼ 0.9).
Likewise, there were no differences in the median baseline
QTc intervals between males randomized to CQ versus AQ-
13, or between females randomized to CQ versus AQ-13.
Effects of AQ-13 and CQ on the QTc interval. Both AQ-13
and CQ prolonged the QTc interval at doses of 600/700 and
1,500/1,750 mg. CQ produced greater prolongation of the
QTc interval than AQ-13 (Table 6).
.......................................................................................................................................................................................
Table 3. Comparative Pharmacokinetics of AQ-13 and CQ at 600 and 700 mg Doses
Parameter
CQ (600 mg)
(n ¼ 24)
AQ-13 (600 mg)
(n ¼ 12) p-Value
AQ-13 (700 mg)
(n ¼ 13) p-Value
a
Cmax (lM) 1.8 (1.3–5.2) 1.4 (0.9–2.4) ,0.01 1.6 (1.2–5.4) 0.22
Tmax (h) 3.0 (1.0–8.0) 4.0 (1.0–8.0) 0.65 4.0 (1.0–8.0) 0.32
AUCw1 (h 3 lM) 90.0 (48.9–212.3) 71.8 (42.8–119.2) ,0.01 96.3 (58.4–183.0) 0.39
AUCs (h 3 lM) 241.2 (179.8–432.4) 140.8 (63.4–351.9) ,0.01 342.1 (168.2–477.2) 0.03
t½ (d) 23.3 (10.2–54.6) 14.3 (6.2–39.3) ,0.01 17.9 (12.5–47.5) 0.48
MRT (d) 24.7 (12.4–49.8) 10.5 (6.0–37.4) ,0.01 23.5 (16.5–59.4) 0.91
Cl/F (l/h) 11.3 (5.7–20.3) 14.7 (7.0–31.1) 0.01 11.8 (8.5–19.1) 0.97
Vd/F (l) 8,672 (2,593–32,503) 6,707 (3,394–14,315) 0.28 6,830 (2,411–63,588) 0.95
All data presented as median (range).
ap-Value for comparison between AQ-13 700 mg and CQ 600 mg doses (Mann-Whitney test for all comparisons).
doi:10.1371/journal.pctr.0020006.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 4. Comparative Pharmacokinetics of AQ-13 and CQ at
1,750 and 1,500 mg Doses
Parameter
CQ (1,500 mg)
(n ¼ 14)
AQ-13 (1,750 mg)
(n ¼ 12) p-Value
Cmax (lM) 3.4 (1.4–5.6) 3.0 (1.2–6.8) 0.28
Tmax (h) 26.3 (25.5–47.5) 27.4 (25.0–49.1) 0.91
AUCw1 (h 3 lM) 311.9 (119.2–440.3) 226.3 (126.8–493.3) 0.31
AUCs (h 3 lM) 636.3 (394.2–1,010.9) 493.1 (267.7–838.7) 0.09
t½ (d) 13.2 (4.0–44.0) 12.9 (3.0–36.6) 0.87
MRT (d) 16.0 (5.7–54.5) 13.4 (8.2–44.5) 0.89
Cl/F (l/h) 9.5 (5.4–20.6) 14.0 (6.8–20.3) 0.03
Clr (l/h) 6.0 (2.4–15.2) 3.3 (2.2–9.7) 0.01
Vd/F (l) 3,721 (1,248–20,516) 6,662 (1,176–25,407) 0.28
All data presented as median (range).
doi:10.1371/journal.pctr.0020006.t004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Randomized Controlled Trial of AQ-13Four hours after drug administration, volunteers who
received 600 mg CQ had a mean 16 ms (95% conﬁdence
interval [CI], 9 to 23 ms) increase in the QTc interval from
baseline, in comparison to an 11 ms (95% CI,, 4 to 18 ms)
increase after 600 or 700 mg AQ-13. When the data were
analyzed by gender, signiﬁcant increases in the QTc interval
were observed only for females with both drugs (AQ-13, 18 ms
increase [95% CI, 10 to 27 ms]; CQ, 22 ms increase [95% CI,
14 to 31 ms]). In contrast, mean QTc interval changes were
not signiﬁcant for males with either AQ-13 or CQ (AQ-13, 1
ms; CQ, 7 ms; p . 0.3 for both). Among the 49 male and
female volunteers who received 600/700 mg AQ-13 or 600 mg
CQ, two volunteers developed QTc intervals greater than 450
ms (467 ms and 457 ms). Both were female, both had received
CQ; neither had any cardiac AEs.
On the other hand, for the 1,750 mg AQ-13, 1,500 mg CQ
dose, after the therapeutic dose, the effects of AQ-13 and CQ
on the QTc interval were parallel to their blood levels—that
is, QTc prolongation was greatest 4 h after the second dose
on day 2, which was the time of the peak blood levels for both
drugs (Figures 4–6). With AQ-13, the mean 6 standard
deviation QTc interval increased from 397 6 16 ms at
baseline to 407 6 11 ms 4 h after the second dose (p¼0.025).
With CQ, the mean QTc interval increased from 396 6 21 ms
to 424 6 19 ms (p , 0.01). The mean increase in the QTc
interval was greater after CQ than AQ-13: 28 ms (95% CI, 18
to 38 ms) versus 10 ms (95% CI, 2 to 17 ms). Figure 4
demonstrates the time course of the effects of the study drugs
on the QTc interval, which then decreased gradually after day
2 as the AQ-13 and CQ blood levels fell. Despite prolongation
of the QTc interval by both CQ and AQ-13, there were no
cardiac AEs (Table 6).
When the data were analyzed by gender, the mean QTc
prolongation tended to be greater with CQ than AQ-13 in
both males and females (males: 16 ms for AQ-13, 95% CI 9 to
23 ms; 31 ms for CQ, 95% CI 16 to 46 ms; females: 12 ms for
AQ-13, 95% CI 4 to 20 ms; 28 ms for CQ, 95% CI 17 to 39 ms).
However, the small number of volunteers in each category
did not permit statistical comparisons between males and
females within drug groups or between drugs. As with the
600/700 mg dose, two volunteers who received the 1,500/1,750
mg dose developed QTc intervals . 450 ms 4 h after dosing
on day 2 (453 ms for both). Both were female, both had
received CQ; neither had any cardiac AEs.
Analysis of QTc interval changes at the individual level
showed that the maximal prolongations of the QTc interval
from baseline at the 600/700 mg dose were 54 ms for CQ and
42 ms for AQ-13. At the 1,500/1,750 mg dose, the maximal
prolongation from baseline for CQ was 63 ms versus 35 ms
for AQ-13. All four volunteers were female, and none
experienced any cardiac AEs. QTc intervals returned to
baseline in all participants by the time of the 2 wk follow-up.
DISCUSSION
Study Design and Interpretation
RCTs. Because these studies were conducted as RCTs
(Figure1),theyaredifferentfromPhaseIclinicaltrialswithout
controls. The rationale for this study design was twofold. First,
thesafetyofCQissufﬁcientlyestablishedthatCQisastandard
against which other drugs are compared. Second, current
.......................................................................................................................................................................................
Table 5. Comparative Pharmacokinetics of AQ-72 and MDCQ at Different Doses of AQ-13 and CQ (median, range)
Parameter MDCQ AQ-72 p-Value
a p-Value
b
600 mg 1,500 mg 600 mg 700 mg 1,750 mg — —
AUCs (lM 3 h) 204.8 (122.6–419.9) 329.7 (159.5–866.5) 210.6 (67.7–309.4) 261.8 (148.0–391.2) 440 (266.8–863.8) 0.08 0.61
t1/2 (d) 31.2 (13.1–59.5) 21.8 (2.8–57.0) 11.1 (6.8–37.0) 12.3 (5.2–37.1) 10.5 (6.6–20.9) ,0.01 0.01
MRT (d) 44.8 (20.8–71.0) 29.0 (5.3–64.4) 16.6 (10.5–51.8) 18.6 (8.0–42.5) 17.4 (10.3–25.6) ,0.01 0.03
Clr (l/h) — 3.8 (2.1–8.2) — — 2.0 (0.9–7.6) — ,0.01
All data presented as median (range).
ap-Value for comparison between doses of 600 mg CQ and AQ-13.
bp-Value for comparisons between 1,500 mg CQ and 1,750 AQ-13.
AQ-72, mono-desethyl AQ-1;. MDCQ, mono-desethylchloroquine.
doi:10.1371/journal.pctr.0020006.t005 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 6. Effects of AQ-13 and CQ on the QTc Interval
Time of QTc Measurement 600/700 mg AQ-13, 600 mg CQ 1,750 mg AQ-13, 1,500 mg CQ
AQ-13 (n ¼ 25) CQ (n ¼ 24) AQ-13 (n ¼ 13) CQ (n ¼ 14)
Baseline 403 6 17 406 6 19 397 6 16 396 6 21
4–5 h post-dose (day 1) 414 6 17 421 6 20 401 6 14 412 6 22
4–5 h post-dose (day 2) NA NA 407 6 11 424 6 18
4–5 h post-dose (day 3) NA NA 400 6 11 417 6 21
2 wk follow-up 405 6 18 403 6 15 402 6 13 412 6 13
All data are presented in milliseconds as mean 6 standard deviation. Data presented in columns 3 and 4 are for 12 volunteers randomized to AQ-13 at the 600 mg dose, plus an
additional 13 volunteers who received 700 mg AQ-13; for 12 volunteers randomized to 600 mg CQ as capsules and an additional 12 volunteers randomized to 600 mg CQ as the
commercially available Sanofi-Winthrop tablets (Aralen). Data in columns 4 and 5 are for 13 volunteers randomized to 1,750 mg AQ-13 and 13 volunteers randomized to 1,500 mg CQ.
NA, not applicable.
doi:10.1371/journal.pctr.0020006.t006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Randomized Controlled Trial of AQ-13expectations of the FDA and the public are markedly different
today from the 1940s when CQ was ﬁrst approved for clinical
use[36,37].Thus,therewasaneedtore-examinethesafetyand
pharmacokinetics of CQ using strategies such as Holter
monitoring that were not available 60 years ago.
As demonstrated in Table 1, the randomization strategy
was effective: volunteers randomized to AQ-13 and CQ had
similar age and sex distributions, similar weights and BMIs,
and similar baseline QTc intervals. In terms of the upcoming
Phase II studies of AQ-13 in Mali (West Africa), it is helpful
that 37% (46/126) of the participants in Phase I were African
or African American. The participation of these Africans and
African Americans makes it less likely that the Phase II studies
in Africa will identify new frequent AEs with AQ-13.
Adverse Events
AEs during the GCRC inpatient stay. Headache, light-
headedness, and GI tract AEs were reported most frequently;
they occurred at similar frequencies with AQ-13 and CQ, and
are known side effects of CQ [3,4,30–34]. Although AQ-13
may produce GI side effects more frequently (nausea,
diarrhea), the number of volunteers studied does not permit
one to conclude that AQ-13 has more GI toxicity than CQ.
Other less common AEs, such as fatigue, blurred vision,
ringing in ears, and rash were mild, transient, and had similar
frequencies in both groups.
AEs identiﬁed during the follow-up visits. At the 2 and 4 wk
follow-up visits, there was no evidence for cardiac, ocular,
hepatic, hematologic, renal, dermatologic, or other end-organ
AEs. Although AEs involving these and other organs have
been reported with AQs previously [31–34], they have
typically been reported in persons treated for prolonged
periods of time (5–10 y or more) at doses of 200–400 mg base
or higher per day [34,38]. The absence of clinically detectable
AEs and the normal laboratory tests in 119 volunteers at the 2
and 4 wk follow-up are consistent with previous reports on the
safety of short-term CQ treatment [3,4,30–33]. The abnormal
liver function test results (ALT, AST, and alkaline phospha-
tase) in one volunteer at the 300 mg dose may be related to
AQ-13. However, all the tests were normal one week later and
no similar hepatic AEs were observed in any volunteer with
higher doses of AQ-13. The AEs observed are consistent with
the hypothesis that AQ-13 is as safe as CQ in humans.
Pharmacokinetics
Results obtained after the 600/700 and 1,500/1,750 mg oral
doses of CQ and AQ-13 are consistent with previous studies;
they demonstrated rapid oral absorption, a multiexponential
declineinbloodconcentrations aftertheCmax, a longterminal
elimination t1/2, and a large Vd/F [39–41]. The estimated CQ
clearance is also in agreement with previous reports [29,42].
However, accurate assessment of the terminal elimination t1/2
and the Vd/F is difﬁcult because of tissue sequestration with
CQ [29,40,42–44] and AQ-13. For example, the 14–24 d
estimate of the terminal elimination t1/2 for CQ agrees with
some reports [40,41], but is shorter than in others [29,42].
With the 700 mg dose, clearance of AQ-13 was less than with
600 mg (medians, 11.8 l/h versus 14.7 l/h; p ¼ 0.01). One
potentialexplanationisthatparticipantswhoreceivedthe700
mg dose were heavier than participants who received 600 mg
(mean weights 6 standard deviation of 83.3 6 17.2 versus 72.0
6 14.1 kg; p , 0.01). As a result, AQ-13 may have distributed
more extensively in participants who received 700 mg because
of extra body fat, which made the drug less available for
elimination, and thus may have affected its clearance [43].
After 1,500 mg CQ, MDCQ was eliminated more slowly
than CQ (MDCQ: terminal t1/2 of 21.8 d, MRT of 29.0 d; CQ:
13.2 and 16.0 d). In contrast, the terminal t1/2 and MRT of AQ-
72 were similar to those of AQ-13 (Tables 4 and 5). The longer
t1/2 and MRT of MDCQ (in comparison to CQ) are consistent
with its lower renal clearance (3.8 l/h versus 6.0 l/h; p ¼ 0.03),
and with the ﬁndings of other investigators [41,42,45]. As with
MDCQ and CQ, the renal clearance of AQ-72 was less than
that of its parent compound, AQ-13 (2.0 l/h versus 3.3 l/h; p ,
0.01). However, the similar t1/2 values and MRTs of AQ-72 and
AQ-13 are inconsistent with the lower Clr of AQ-72; these
ﬁndings suggest that another pathway, such as metabolism of
AQ-72 to AQ-73 by the CYP450 system, may account for this
difference. The greater urinary excretion of AQ-13 and CQ
than their more water-soluble metabolites (Tables 4 and 5)
[26] is consistent with the active transport of CQ, and possibly
AQ-13, by organic cation transporters such as organic cation
transporter-like 2 (ORCTL2) [46]. The paradoxical observa-
tion that AQ-72 has both a shorter MRT in the blood and a
lower Clr than MDCQ (Table 5) may be explained by a greater
role for CYP450 metabolism (N-dealkylation) with AQ-13
than CQ [47]; this hypothesis is also consistent with the
observation that the urinary ratio for AQ-73/AQ-13 was twice
the urinary ratio for BDCQ/CQ, consistent with greater
conversion of AQ-72 to AQ-73 than of MDCQ to BDCQ.
Effects of AQ-13 and CQ on the QTc Interval
Previous animal [48,49] and human studies [28,50,51] have
shown that CQ prolongs the QT interval. The results reported
here conﬁrm those observations, and establish the dose
(blood-level)-related nature of QTc prolongation by CQ. At
the 600 mg dose, CQ prolonged the mean QTc interval by 15
ms (Table 6). The same effect (16 ms QTc prolongation) was
seen 4 h after the ﬁrst 600 mg CQ dose (on day 1) with the
1,500 mg therapeutic dose of CQ (Figure 4). The QTc interval
increased by an additional 12 ms after the second 600 mg CQ
dose on day 2 (mean increase of 27 ms relative to baseline),
and then decreased gradually as CQ blood levels fell after the
Figure 4. ChangesintheQTcIntervalafter1,750mgAQ-13or1,500mgCQ
Changes in the QTc interval from baseline were determined using the Rozinn
Electronics system software to evaluate the Holter recordings.
doi:10.1371/journal.pctr.0020006.g004
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Randomized Controlled Trial of AQ-13third (300 mg) dose on day 3, and thereafter, thus demonstrat-
ing a dose (blood level)–response relationship between the CQ
blood level and QTc prolongation. These results are consis-
tent with a previous study that suggested a dose-dependent
effect of CQ on the QT interval after oral administration [28].
Although a similar pattern was observed with AQ-13, the
effects of AQ-13 on the QTc interval were less than those of
CQ. For example, the ﬁrst 700 mg dose at the 1,750 mg level
prolonged the mean QTc interval by 4 ms, and the second by
an additional 6 ms. The QTc interval then decreased gradually
thereafter as the AQ-13 blood levels fell (Figure 4; Table 6).
When the effects of AQ-13 and CQ were analyzed by gender,
QTc prolongation was signiﬁcant only for females after the
600 and 700 mg doses. In contrast, signiﬁcant QTc prolonga-
tion was observed in both males and females after the 1,500/
1,750 mg dose (Table 6). This discrepancy could be due to the
known increased vulnerability of women to drug-induced
QTc interval prolongation [52,53], which caused this effect to
appear in them at doses lower than in men; alternatively, this
could be a chance ﬁnding because of the small sample sizes
involved. These results establish that AQ-13, like CQ, prolongs
the QTc interval in humans and that CQ produces greater
QTc prolongation than AQ-13. However, the signiﬁcance of
these observations is unclear because no arrhythmias or other
cardiac AEs were observed in any participants.
Figure 5. Modeled Concentration-Time Data (1,750 mg AQ-13 Therapeutic Dose)
Individual volunteers received daily oral doses of AQ-13 for 3 d (day 1, 700; day 2, 700; and day 3, 350 mg). Blood samples were then obtained, analyzed, and
modeled (see Methods).
doi:10.1371/journal.pctr.0020006.g005
Figure 6. Modeled Concentration–Time Data (1,500 mg CQ Therapeutic Dose)
Individual volunteers received daily oral doses of CQ for 3 d (day 1, 600; day 2, 600; and day 3, 300 mg). Blood samples were then obtained, analyzed and
modeled (see Methods).
doi:10.1371/journal.pctr.0020006.g006
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Generalizability
TheresultsreportedheresuggestthattheAEsofAQ-13may
be no different from those of CQ, that higher doses of AQ-13
than CQ may be necessary to produce similar blood levels and
AUCs, and that AQ-13 may produce less QT prolongation
than CQ in humans. However, given the small numbers and
nonrepresentative selection of study participants, the extent
to which these results are generalizable is unclear.
Overall Evidence
The results reported here are consistent with the hypoth-
eses underlying the objectives of these studies. First, the
similar AEs observed with AQ-13 and CQ are consistent with
the hypothesis that AQs with structures similar to CQ should
be similarly safe in humans. Second, they demonstrate that
AQ-13, an AQ analogous to CQ, has similar linear pharma-
cokinetics in human volunteers, despite the fact that it
requires a larger dose to achieve equivalent drug exposure
because of a more rapid clearance. These results are also
consistent with the preclinical studies, which suggested that
the AEs of AQ-13 and CQ would be similar and that a dose
adjustment would be necessary for AQ-13 because of its more
rapid clearance [17,18]. Because this Phase I study has
demonstrated the safety of AQ-13 doses up to 1,750 mg, the
next logical study (after examining the effects of a fatty meal
on the absorption of AQ-13) is a dose-ﬁnding efﬁcacy (Phase
2) study in humans with uncomplicated P. falciparum malaria.
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